NZ509178A - Compositions and methods for therapy and diagnosis of prostate cancer - Google Patents
Compositions and methods for therapy and diagnosis of prostate cancerInfo
- Publication number
- NZ509178A NZ509178A NZ509178A NZ50917899A NZ509178A NZ 509178 A NZ509178 A NZ 509178A NZ 509178 A NZ509178 A NZ 509178A NZ 50917899 A NZ50917899 A NZ 50917899A NZ 509178 A NZ509178 A NZ 509178A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- cdna sequence
- polypeptide
- polynucleotide
- prostate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 107
- 206010060862 Prostate cancer Diseases 0.000 title claims description 27
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title description 35
- 238000003745 diagnosis Methods 0.000 title description 8
- 238000002560 therapeutic procedure Methods 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 282
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 229
- 229920001184 polypeptide Polymers 0.000 claims abstract description 221
- 208000023958 prostate neoplasm Diseases 0.000 claims abstract description 218
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 213
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 143
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 128
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 125
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 125
- 239000002157 polynucleotide Substances 0.000 claims abstract description 125
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 83
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 95
- 230000014509 gene expression Effects 0.000 claims description 91
- 201000011510 cancer Diseases 0.000 claims description 72
- 239000011230 binding agent Substances 0.000 claims description 59
- 239000000427 antigen Substances 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 241000282414 Homo sapiens Species 0.000 claims description 53
- 239000000523 sample Substances 0.000 claims description 49
- 238000003556 assay Methods 0.000 claims description 46
- 230000027455 binding Effects 0.000 claims description 40
- 210000004443 dendritic cell Anatomy 0.000 claims description 38
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 37
- 239000012472 biological sample Substances 0.000 claims description 35
- 238000003752 polymerase chain reaction Methods 0.000 claims description 35
- 108020001507 fusion proteins Proteins 0.000 claims description 28
- 102000037865 fusion proteins Human genes 0.000 claims description 28
- 239000003623 enhancer Substances 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 25
- 108091034117 Oligonucleotide Proteins 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 22
- 238000000338 in vitro Methods 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 230000015788 innate immune response Effects 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 125000006853 reporter group Chemical group 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 17
- 230000000295 complement effect Effects 0.000 claims description 14
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 108090001090 Lectins Proteins 0.000 claims description 2
- 102000004856 Lectins Human genes 0.000 claims description 2
- 101710120037 Toxin CcdB Proteins 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 30
- 238000002360 preparation method Methods 0.000 abstract description 9
- 239000002299 complementary DNA Substances 0.000 description 554
- 235000018102 proteins Nutrition 0.000 description 125
- 210000002307 prostate Anatomy 0.000 description 117
- 210000001519 tissue Anatomy 0.000 description 111
- 108020004414 DNA Proteins 0.000 description 32
- 210000002950 fibroblast Anatomy 0.000 description 29
- 239000013615 primer Substances 0.000 description 28
- 108091060211 Expressed sequence tag Proteins 0.000 description 27
- 108020004999 messenger RNA Proteins 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- 150000001413 amino acids Chemical class 0.000 description 22
- 125000005647 linker group Chemical group 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 20
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 20
- 230000002018 overexpression Effects 0.000 description 20
- 108020004635 Complementary DNA Proteins 0.000 description 18
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 18
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 18
- 210000001072 colon Anatomy 0.000 description 18
- 238000002955 isolation Methods 0.000 description 18
- 208000026310 Breast neoplasm Diseases 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000007792 addition Methods 0.000 description 13
- 230000003321 amplification Effects 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 210000000496 pancreas Anatomy 0.000 description 13
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 12
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 11
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 11
- 230000036961 partial effect Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000010208 microarray analysis Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000001550 testis Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000003155 DNA primer Substances 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- -1 acetyl- methyl- Chemical group 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003292 diminished effect Effects 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000012775 microarray technology Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101710103262 Glandular kallikrein Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102100034681 Myeloblastin Human genes 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102000015428 Prostatic Secretory Proteins Human genes 0.000 description 4
- 108010064730 Prostatic Secretory Proteins Proteins 0.000 description 4
- 102000057032 Tissue Kallikreins Human genes 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 108010023472 cytochrome C oxidase subunit II Proteins 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 210000003079 salivary gland Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- AHOKKYCUWBLDST-QYULHYBRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2,6-diaminohexanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=CC=C1 AHOKKYCUWBLDST-QYULHYBRSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000011510 Elispot assay Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 101000655476 Homo sapiens Probable mitochondrial glutathione transporter SLC25A39 Proteins 0.000 description 3
- 101100140242 Homo sapiens RDH11 gene Proteins 0.000 description 3
- 101000580092 Homo sapiens RNA-binding protein 10 Proteins 0.000 description 3
- 101000711466 Homo sapiens SAM pointed domain-containing Ets transcription factor Proteins 0.000 description 3
- 101000818836 Homo sapiens Zinc finger protein 609 Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102100032871 Probable mitochondrial glutathione transporter SLC25A39 Human genes 0.000 description 3
- 101710188053 Protein D Proteins 0.000 description 3
- 102100027514 RNA-binding protein 10 Human genes 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101710132893 Resolvase Proteins 0.000 description 3
- 102100023916 Retinol dehydrogenase 11 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 3
- 108060008539 Transglutaminase Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 102100037814 Vigilin Human genes 0.000 description 3
- 102100021355 Zinc finger protein 609 Human genes 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001094 effect on targets Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 108010092427 high density lipoprotein binding protein Proteins 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 102000003601 transglutaminase Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101001072881 Homo sapiens Phosphoglucomutase-like protein 5 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 2
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000019394 Serine hydroxymethyltransferases Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007798 limiting dilution analysis Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000011410 subtraction method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010076057 2-arylpropionyl-CoA epimerase Proteins 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 108010029714 A2-binding peptide Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102100037068 Cytoplasmic dynein 1 light intermediate chain 1 Human genes 0.000 description 1
- 101710108456 Cytoplasmic dynein 1 light intermediate chain 1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical group [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000783783 Homo sapiens ATP-binding cassette sub-family F member 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000942612 Homo sapiens Condensin-2 complex subunit D3 Proteins 0.000 description 1
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001041145 Homo sapiens Homeobox protein Hox-B13 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001108330 Homo sapiens Natural resistance-associated macrophage protein 2 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101100406818 Homo sapiens PAGE4 gene Proteins 0.000 description 1
- 101000854603 Homo sapiens Protein FAM168A Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 1
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100348669 Mus musculus Nkx3-1 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102100021867 Natural resistance-associated macrophage protein 2 Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100023240 P antigen family member 4 Human genes 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102100036635 Phosphoglucomutase-like protein 5 Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102100020938 Protein FAM168A Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108091006618 SLC11A2 Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101000834993 Sus scrofa Transitional endoplasmic reticulum ATPase Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical group 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/58—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/116,134 US7008772B1 (en) | 1997-02-25 | 1998-07-14 | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| US09/115,453 US6657056B2 (en) | 1997-02-25 | 1998-07-14 | Compounds for immunotherapy of prostate cancer and methods for their use |
| US15982298A | 1998-09-23 | 1998-09-23 | |
| US09/159,812 US6613872B1 (en) | 1997-02-25 | 1998-09-23 | Compounds for immunotherapy of prostate cancer and methods for their use |
| US09/232,149 US6465611B1 (en) | 1997-02-25 | 1999-01-15 | Compounds for immunotherapy of prostate cancer and methods for their use |
| US09/232,880 US7270980B2 (en) | 1997-02-25 | 1999-01-15 | Compounds for immunodiagnosis of prostate cancer and methods for their use |
| US28894699A | 1999-04-09 | 1999-04-09 | |
| PCT/US1999/015838 WO2000004149A2 (en) | 1998-07-14 | 1999-07-14 | Compositions and methods for therapy and diagnosis of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ509178A true NZ509178A (en) | 2004-04-30 |
Family
ID=27568734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ509178A NZ509178A (en) | 1998-07-14 | 1999-07-14 | Compositions and methods for therapy and diagnosis of prostate cancer |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP1870466A3 (OSRAM) |
| JP (1) | JP2002520054A (OSRAM) |
| KR (2) | KR20070112860A (OSRAM) |
| CN (1) | CN100419079C (OSRAM) |
| AU (2) | AU762812B2 (OSRAM) |
| BR (1) | BR9912007A (OSRAM) |
| CA (1) | CA2334038A1 (OSRAM) |
| CZ (1) | CZ2001149A3 (OSRAM) |
| HU (1) | HUP0203035A3 (OSRAM) |
| IL (1) | IL140845A0 (OSRAM) |
| NO (1) | NO20010196L (OSRAM) |
| NZ (1) | NZ509178A (OSRAM) |
| PL (1) | PL200772B1 (OSRAM) |
| SA (1) | SA99200618B1 (OSRAM) |
| TR (1) | TR200100916T2 (OSRAM) |
| TW (2) | TW200728465A (OSRAM) |
| WO (1) | WO2000004149A2 (OSRAM) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828431B1 (en) * | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6620922B1 (en) | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US6894146B1 (en) | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6759515B1 (en) | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6657056B2 (en) | 1997-02-25 | 2003-12-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6630305B1 (en) | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6818751B1 (en) | 1997-08-01 | 2004-11-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| AU7019498A (en) | 1997-04-10 | 1998-10-30 | Diagnocure Inc. | Pca3, pca3 genes, and methods of use |
| US6365369B1 (en) | 1998-04-01 | 2002-04-02 | Human Genome Sciences, Inc. | Prostate specific secreted protein |
| US6861215B1 (en) | 1998-05-21 | 2005-03-01 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging prostate cancer |
| US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| DE69941187D1 (de) | 1998-06-01 | 2009-09-10 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| CA2344552A1 (en) * | 1998-10-02 | 2000-04-13 | Urogenesys, Inc. | Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6 |
| US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US6528054B1 (en) * | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| IL145719A0 (en) * | 1999-04-09 | 2002-07-25 | Corixa Corp | Polypeptides encoded by nucleotide sequences expressed in breast tumor tissue and uses thereof |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| AU4484400A (en) * | 1999-04-23 | 2000-11-10 | University Of Washington | Prostate-specific polynucleotides, polypeptides and their methods of use |
| WO2000071711A2 (en) * | 1999-05-20 | 2000-11-30 | Fahri Saatcioglu | Differentially expressed genes in prostate cancer |
| WO2001004143A2 (en) * | 1999-07-13 | 2001-01-18 | Smithkline Beecham Biologicals S.A. | Prostase vaccine |
| JP2003510075A (ja) | 1999-09-29 | 2003-03-18 | ディグノキュアー・インコーポレーテッド | 良性および悪性の前立腺組織におけるｐｃａ３メッセンジャーｒｎａ種 |
| AU7917200A (en) * | 1999-09-30 | 2001-04-30 | Institut Pasteur | Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences |
| AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| US7208280B2 (en) | 1999-10-05 | 2007-04-24 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| ATE524549T1 (de) * | 1999-10-05 | 2011-09-15 | Agensys Inc | G protein-gekoppelter in prostatakrebs hochexprimierter rezeptor und seine verwendungen |
| AU7753700A (en) * | 1999-10-07 | 2001-05-10 | Schering Aktiengesellschaft | Dna encoding prost 07 polypeptide |
| JP2004537252A (ja) * | 1999-11-12 | 2004-12-16 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
| MXPA02006934A (es) * | 2000-01-14 | 2003-01-28 | Corixa Corp | Composiciones y metodos para la terapia y diagnostico de cancer de prostata. |
| AU2001236782A1 (en) * | 2000-02-08 | 2001-08-20 | Agensys, Inc. | 34p3d7: a tissue specific protein highly expressed in prostate cancer |
| AU2001241541A1 (en) * | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| WO2001070979A2 (en) * | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| US7611892B2 (en) | 2000-03-24 | 2009-11-03 | President And Fellows Of Harvard College | Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| AU2001249549A1 (en) * | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| GB0015736D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Biolog | Vaccine |
| GB0015722D0 (en) * | 2000-06-27 | 2000-08-16 | Smithkline Beecham Sa | Vaccine |
| DE60131670T2 (de) | 2000-10-18 | 2008-10-30 | Glaxosmithkline Biologicals S.A. | Impfstoffe gegen Krebskrankheiten |
| US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| IL155952A0 (en) | 2000-11-28 | 2003-12-23 | Wyeth Corp | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US7037652B2 (en) | 2000-11-28 | 2006-05-02 | Wyeth | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| JP2005504513A (ja) * | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| AU2002336446B2 (en) | 2001-09-06 | 2008-03-06 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| AU2002258689C1 (en) * | 2002-04-01 | 2008-04-24 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
| KR20050010040A (ko) * | 2002-06-11 | 2005-01-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| EP1511513A2 (en) * | 2002-06-11 | 2005-03-09 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions comprising a xenogenic prostate protein p501s |
| WO2004016733A2 (en) | 2002-08-16 | 2004-02-26 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| WO2004070056A2 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| CA2678736A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional il-2 - il-18 fusion proteins |
| NZ550816A (en) | 2004-04-22 | 2009-12-24 | Agensys Inc | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| CA2622295C (en) | 2005-09-12 | 2019-01-15 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US9957569B2 (en) | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2008016111A1 (fr) | 2006-08-04 | 2008-02-07 | Ajinomoto Co., Inc. | Procédé permettant d'évaluer un cancer du poumon, dispositif d'évaluation d'un cancer du poumon, procédé d'évaluation d'un cancer du poumon, système d'évaluation d'un cancer du poumon, programme d'évaluation d' |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PT2484375T (pt) | 2006-09-26 | 2018-07-09 | Infectious Disease Res Inst | Composição para vacina contendo adjuvante sintético |
| MX2009003938A (es) | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
| WO2008075663A1 (ja) | 2006-12-21 | 2008-06-26 | Ajinomoto Co., Inc. | 大腸癌の評価方法、ならびに大腸癌評価装置、大腸癌評価方法、大腸癌評価システム、大腸癌評価プログラムおよび記録媒体 |
| JP5746810B2 (ja) | 2006-12-21 | 2015-07-08 | 味の素株式会社 | 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体 |
| ATE533861T1 (de) | 2007-07-06 | 2011-12-15 | Univ Michigan | Mipol1-etv1-gen-neuanordnungen |
| US8106037B2 (en) | 2007-08-03 | 2012-01-31 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
| KR100976218B1 (ko) | 2008-05-26 | 2010-08-17 | 한국표준과학연구원 | 비행시간이차이온질량분광법을 이용한 질병의 진단 방법,질병 지표의 스크린 방법, 및 질병 지표 |
| CN102066946B (zh) * | 2008-06-20 | 2016-08-31 | 味之素株式会社 | 前列腺疾病的评价方法 |
| KR20160127146A (ko) * | 2008-08-05 | 2016-11-02 | 도레이 카부시키가이샤 | 면역 유도제 |
| AU2009278386B2 (en) | 2008-08-05 | 2015-05-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
| DK2733492T3 (en) | 2008-08-05 | 2016-04-25 | Toray Industries | Method for detection of cancer |
| CN102439176B (zh) * | 2009-05-12 | 2018-11-23 | 皇家飞利浦电子股份有限公司 | 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7 |
| HRP20161585T1 (hr) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže |
| WO2011034906A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| ES2583777T3 (es) | 2010-02-04 | 2016-09-22 | Toray Industries, Inc. | Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer |
| US9180187B2 (en) | 2010-02-04 | 2015-11-10 | Toray Industries, Inc. | Medicament for treating and/or preventing cancer |
| RU2603742C2 (ru) | 2010-02-04 | 2016-11-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| PL2532366T3 (pl) | 2010-02-04 | 2017-02-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
| CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| US8945556B2 (en) | 2010-11-19 | 2015-02-03 | The Regents Of The University Of Michigan | RAF gene fusions |
| EA201391183A1 (ru) | 2011-02-15 | 2014-02-28 | Иммьюн Дизайн Корп. | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP2740798B1 (en) | 2011-08-04 | 2016-12-07 | Toray Industries, Inc. | Cancer treatment and/or prevention drug composition |
| HUE030137T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | Pharmaceutical preparation for the treatment and / or prevention of cancer |
| MX351682B (es) | 2011-08-04 | 2017-10-25 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CA2844040C (en) | 2011-08-04 | 2019-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| MX351414B (es) | 2011-08-04 | 2017-10-13 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| JP6015448B2 (ja) | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| DK2811981T3 (da) | 2012-02-07 | 2019-06-11 | Infectious Disease Res Inst | Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf |
| WO2013125630A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| MX360208B (es) | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| DK2824114T3 (da) | 2012-02-21 | 2019-07-29 | Toray Industries | Farmaceutisk sammensætning til behandling af cancer |
| CA2864869C (en) | 2012-02-21 | 2021-10-19 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| KR102052400B1 (ko) | 2012-03-30 | 2019-12-06 | 도레이 카부시키가이샤 | 담낭암의 치료 및/또는 예방용 의약 조성물 |
| MX358224B (es) | 2012-03-30 | 2018-08-10 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. |
| US9555099B2 (en) | 2012-05-16 | 2017-01-31 | Immune Design Corp. | Vaccines for HSV-2 |
| HUE064187T2 (hu) * | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| EP2876446B1 (en) | 2012-07-19 | 2018-12-26 | Toray Industries, Inc. | Method for detecting cancer |
| BR112015001100A2 (pt) | 2012-07-19 | 2018-03-27 | Toray Industries, Inc. | método de detecção de câncer |
| US10092634B2 (en) * | 2012-09-11 | 2018-10-09 | Oncotherapy Science, Inc. | UBE2T peptides and vaccines containing the same |
| EP3587455A1 (en) | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| AU2014253791B2 (en) | 2013-04-18 | 2019-05-02 | Immune Design Corp. | GLA monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| IL310015B1 (en) | 2013-12-31 | 2025-10-01 | Access To Advanced Health Inst | Single vial formulation |
| CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| JOP20200228A1 (ar) * | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
| CN108472350A (zh) * | 2016-01-08 | 2018-08-31 | 瓦西博迪公司 | 新表位rna癌症疫苗 |
| US11162945B2 (en) | 2016-04-11 | 2021-11-02 | Board Of Regents, The University Of Texas System | Methods and compositions for detecting single T cell receptor affinity and sequence |
| BR112018073690B1 (pt) | 2016-05-16 | 2022-05-24 | Infectious Disease Research Institute | Formulação contendo agonista de tlr e métodos de uso |
| EP3458028A1 (en) | 2016-05-16 | 2019-03-27 | Infectious Disease Research Institute | Pegylated liposomes and methods of use |
| CA3023271A1 (en) | 2016-06-01 | 2017-12-07 | Infectious Disease Research Institute | Nanoalum particles containing a sizing agent |
| AU2018247767B2 (en) | 2017-04-03 | 2025-01-30 | F. Hoffmann-La Roche Ag | Antibodies binding to STEAP-1 |
| KR20240096685A (ko) | 2017-06-15 | 2024-06-26 | 액세스 투 어드밴스드 헬스 인스티튜트 | 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도 |
| CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
| JP2022512921A (ja) * | 2018-11-07 | 2022-02-07 | アコーオス インコーポレイテッド | 有毛細胞の分化を誘導する組成物及び方法 |
| CN111000858B (zh) * | 2019-05-10 | 2021-04-09 | 常州市第二人民医院 | Nupr1抑制剂在制备膀胱癌治疗药物中的用途 |
| CA3141577A1 (en) | 2019-05-25 | 2020-12-03 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| JP2023522198A (ja) * | 2020-04-17 | 2023-05-29 | ザ フランシス クリック インスティチュート リミティッド | 黒色腫を治療するためのｃｔｌ抗原の融合タンパク質 |
| CN111968751B (zh) * | 2020-06-29 | 2021-10-19 | 金电联行（北京）信息技术有限公司 | 一种使用多基线校正模型的传染病趋势预测方法与系统 |
| AU2021335334A1 (en) | 2020-09-04 | 2023-04-20 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
| CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
| CA3173408A1 (en) | 2020-12-23 | 2022-06-30 | Access To Advanced Health Institute | Solanesol vaccine adjuvants and methods of preparing same |
| CA3266697A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041289A (en) * | 1987-11-13 | 1991-08-20 | Becton Dickinson And Company | Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells |
| CA2030212A1 (en) * | 1989-11-22 | 1991-05-23 | Judson V. Edwards | Peptides |
| WO1996034012A1 (en) * | 1995-04-28 | 1996-10-31 | Takeda Chemical Industries, Ltd. | Cyclic pentapeptide lh-rh receptor antagonists |
| KR19990087802A (ko) * | 1996-03-15 | 1999-12-27 | 길리스 스티브 | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 |
| AR012035A1 (es) * | 1997-02-25 | 2000-09-27 | Corixa Corp | Metodo para detectar el cancer de prostata, metodo para monitorear el desarrollo del cancer de prostata, anticuerpo monoclonal que se une a un polipeptido, una cantidad terapeutica eficaz de anticuerpos monoclonales para preparar medicamentos y equipo para diagnostico |
| CA2281952C (en) * | 1997-02-25 | 2011-07-19 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| WO1998050567A1 (en) * | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
-
1999
- 1999-07-14 AU AU53148/99A patent/AU762812B2/en not_active Ceased
- 1999-07-14 TR TR2001/00916T patent/TR200100916T2/xx unknown
- 1999-07-14 CZ CZ2001149A patent/CZ2001149A3/cs unknown
- 1999-07-14 TW TW095142289A patent/TW200728465A/zh unknown
- 1999-07-14 BR BR9912007-0A patent/BR9912007A/pt not_active Application Discontinuation
- 1999-07-14 TW TW094116927A patent/TW200532020A/zh unknown
- 1999-07-14 KR KR1020077023762A patent/KR20070112860A/ko not_active Ceased
- 1999-07-14 EP EP07015347A patent/EP1870466A3/en not_active Withdrawn
- 1999-07-14 CN CNB998103349A patent/CN100419079C/zh not_active Expired - Fee Related
- 1999-07-14 IL IL14084599A patent/IL140845A0/xx unknown
- 1999-07-14 EP EP99938735A patent/EP1097208A2/en not_active Withdrawn
- 1999-07-14 HU HU0203035A patent/HUP0203035A3/hu unknown
- 1999-07-14 JP JP2000560247A patent/JP2002520054A/ja active Pending
- 1999-07-14 NZ NZ509178A patent/NZ509178A/en unknown
- 1999-07-14 WO PCT/US1999/015838 patent/WO2000004149A2/en not_active Ceased
- 1999-07-14 PL PL346359A patent/PL200772B1/pl not_active IP Right Cessation
- 1999-07-14 CA CA002334038A patent/CA2334038A1/en not_active Abandoned
- 1999-07-14 KR KR1020017000549A patent/KR20010083111A/ko not_active Withdrawn
- 1999-09-28 SA SA99200618A patent/SA99200618B1/ar unknown
-
2001
- 2001-01-12 NO NO20010196A patent/NO20010196L/no not_active Application Discontinuation
-
2003
- 2003-09-22 AU AU2003248213A patent/AU2003248213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0203035A2 (hu) | 2002-12-28 |
| AU5314899A (en) | 2000-02-07 |
| WO2000004149A3 (en) | 2000-07-20 |
| KR20010083111A (ko) | 2001-08-31 |
| EP1870466A2 (en) | 2007-12-26 |
| IL140845A0 (en) | 2002-02-10 |
| CN1315998A (zh) | 2001-10-03 |
| CN100419079C (zh) | 2008-09-17 |
| JP2002520054A (ja) | 2002-07-09 |
| HUP0203035A3 (en) | 2007-12-28 |
| EP1097208A2 (en) | 2001-05-09 |
| EP1870466A3 (en) | 2008-03-19 |
| WO2000004149A2 (en) | 2000-01-27 |
| CZ2001149A3 (cs) | 2002-02-13 |
| NO20010196L (no) | 2001-03-12 |
| BR9912007A (pt) | 2002-01-29 |
| KR20070112860A (ko) | 2007-11-27 |
| AU762812B2 (en) | 2003-07-03 |
| TW200532020A (en) | 2005-10-01 |
| TW200728465A (en) | 2007-08-01 |
| TR200100916T2 (OSRAM) | 2002-06-21 |
| SA99200618B1 (ar) | 2007-01-20 |
| NO20010196D0 (no) | 2001-01-12 |
| AU2003248213A1 (en) | 2003-10-30 |
| CA2334038A1 (en) | 2000-01-27 |
| PL200772B1 (pl) | 2009-02-27 |
| PL346359A1 (en) | 2002-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1870466A2 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
| EP1169347B1 (en) | Compounds and methods for therapy and diagnosis of lung cancer | |
| EP1183348B1 (en) | Compositions for the treatment and diagnosis of breast cancer and methods for their use | |
| WO2001025272A2 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
| RU2234942C2 (ru) | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид | |
| WO2001034802A9 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| US7074898B2 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
| WO2000036107A2 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
| WO2000060077A2 (en) | Compounds for therapy and diagnosis of lung cancer and methods for their use | |
| EP1767636A2 (en) | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use | |
| US20010055596A1 (en) | Compositions and methods for therapy and diagnosis of colon cancer | |
| EP1242598A2 (en) | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use | |
| JP2002540789A5 (OSRAM) | ||
| JP2002540789A (ja) | 乳癌の処置および診断のための組成物ならびにそれらの使用方法 | |
| WO2001051513A2 (en) | Ovarian tumor-associated sequences | |
| NZ567750A (en) | Compositions and uses for cancer therapy | |
| US7048931B1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
| US6933363B1 (en) | Compositions and methods for therapy and diagnosis of lung cancer | |
| US7270980B2 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
| CA2613125A1 (en) | Compositions and methods for therapy and diagnosis of prostate cancer | |
| JP2009142284A (ja) | 前立腺癌の治療および診断のための組成物および方法 | |
| WO2001027276A2 (en) | Dna sequences from breast tumor and uses thereof | |
| AU2007216683A1 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |